Stem Cell Therapy Market Forecasts to 2028 - Global Analysis By Product, Therapy Type, Technology, Application, End User and By Geography

According to Stratistics MRC, the Global Stem Cell Therapy Market is accounted for $257 million in 2022 and is expected to reach $722.4 million by 2028 growing at a CAGR of 18.8% during the forecast period. Humans and animals both have stem cells, which are the most valuable cells in the body. Stem cells are cells that have the ability to proliferate and grow into practically any cell type in the body, and they are used in surgery and medicine. There are two types of stem cells: adult stem cells and embryonic stem cells. Embryonic stem cells are stem cells derived from human embryos (ESCs). They are pluripotent, which means they can develop into almost any type of cell in the body. Stem cell therapy is also known as regenerative medicine or centrepiece therapy. Regenerative medications have the ability to regenerate cells and replace those that have been damaged or perished.

According to estimates from the International Agency for Research on Cancer 2020, 1 in 5 people will develop cancer at some point in their lives, and 1 in 8 men and 1 in 11 women will pass away.

Market Dynamics:

Driver:

The rise in prevalence and incidence of chronic diseases

Chronic illnesses affect the vast majority of individuals worldwide. One in in three adults globally suffers from a chronic illness. Many people's health and quality of life have been negatively influenced by chronic diseases. Cancer, musculoskeletal and neurological problems, chronic injuries, cardiovascular and gastrointestinal conditions, and cancer can all lead to hospitalisation, long-term incapacity, a reduction in quality of life, and even death. Mesenchymal stem cells penetrate and integrate into various organs, treating lung, spinal cord, autoimmune illnesses, liver, bone, and cartilage diseases, and treating multiple organ damage. The use of stem cells in the treatment of inflammatory, immune system, and degenerative tissue diseases is a successful method.

Restraint:

Ethical concerns related to embryonic stem cells

Research into the therapeutic potential of embryonic stem cells (ESC) are linked to a number of ethical concerns related to the destruction of human embryos. In the future, a lack of clear federal policies defining what can be supported in embryo-based stem cell research or therapy development may limit market expansion to some extent. Furthermore, the complexities of legislation in this sector necessitate government guidelines that can assist researchers, scientists, and pharmaceutical companies in developing ESC therapy and facilitating its commercialization.

Opportunity:

Availability of funding for stem cell research

Stem cell research funding has increased in recent years, owing to the need for novel therapeutic approaches in patients with cardiovascular, neurological, and autoimmune illnesses. The NIH funding for stem cell research reached a new high in 2018, with a year-on-year increase of more than 5%. This trend is projected to continue with the increase in financing efforts planned in 2021. For example, in September 2021, the California Institute for Regenerative Medicine awarded Stanford Research a USD 31 million funding to launch first-in-human studies of stem cells in the treatment of heart failure, stroke, and spinal cord tumours.

Threat:

High cost of treatment

The high cost of cell therapy has limited market expansion. Cell therapies have developed as a prominent treatment option as people seek out the most recent therapy options. Despite the significant increase in demand, cell therapies remain too expensive to try. Simple joint injections can cost up to $1,000 depending on the situation, whereas more sophisticated surgeries might cost up to $100,000. The average cost of stem cell therapy in the United States is expected to be between $4,000 and $8,000 per patient in 2020. As a result, the high cost of treatment limits the expansion of the stem cell therapy market.

COVID-19 Impact:

The COVID-19 pandemic had little effect on the stem cell therapy industry. The market saw a lot of activity because many research and government entities were focused on finding rapid and effective solutions to cure and prevent dangerous disorders like COVID-19. In fact, the pandemic provided the impetus needed to launch worldwide regenerative medicine clinical trials. Several clinical investigations have confirmed that MSC therapy could be a viable treatment option for COVID-19 patients, particularly those with acute respiratory distress syndrome.

The autologous segment is expected to be the largest during the forecast period

The autologous segment is estimated to have a lucrative growth, because of the increased usage of autologous stem cells and the availability of a variety of stem cell products. Recent advances in cellular technology have contributed to a better understanding of numerous disease cells and their metabolism at the molecular level, pushing the demand for stem cell therapies for treatment. Affordability, better patient survival rate, no need to identify an HLA-matched donor, and minimal risk of graft-versus-host disease are all expected to drive the expansion of this segment.

The cell acquisition segment is expected to have the highest CAGR during the forecast period

The cell acquisition segment is anticipated to witness the fastest CAGR growth during the forecast period. The discovery of embryonic stem cells has paved the path for the development of innovative treatments for a variety of ailments. These cells are pluripotent, which means they can be utilised to differentiate many different types of cells in the body. Obtaining embryonic cells directly from the embryo, on the other hand, has created ethical difficulties. As a result, researchers discovered an alternative-iPS cells. Cell acquisition is further subdivided into bone marrow harvest, umbilical blood cord harvest, and apheresis.

Region with highest share:

North America is projected to hold the largest market share during the forecast period, because of the robust biotechnology industry, the domination of major key firms, considerable R&D efforts, and the promotion of individualised medications. Furthermore, this sector's rise can be attributable to a growing government initiative to promote stem cell therapy. For example, in March 2020, the Canadian government invested around USD 7 million towards regenerative medicine and stem cell research. It will support the country's expansion in the regenerative medicine sector by funding nine transnational initiatives and four clinical trials.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period, because of the development of stem cell-based medicines, government initiatives for producing regenerative drugs, the establishment of multiple stem cell banks, and the region's growing clinical studies for genetic engineering and biomedical research. For example, the government of India has established cutting-edge stem cell research facilities in 40 top health research and educational institutes by February 2022.

Key players in the market:

Some of the key players profiled in the Stem Cell Therapy Market include: CORESTEM, Regrow Biosciences Pvt Ltd., Takeda Pharmaceutical Company Limited, MEDIPOST Co., Ltd., Orthofix Holdings, Inc., Smith & Nephew plc, Novadip Biosciences, Fujifilm Holding Corporation, Astellas Pharma Inc., Allele Biotechnology and Pharmaceuticals, Inc., NuVasive, Inc., Mesoblast Ltd., Anterogen.Co., Ltd.,JCR Pharmaceuticals Co., Ltd. and AlloSource.

Key Developments:

In July 2022, CORESTEM (South Korea) continued enrolling participants for the Phase 3 clinical trial of NeuroNata-R. This therapy has received conditional approval for treating ALS patients in South Korea.

Products Covered:

• Human Embryonic Stem Cells (HESCs)
• Very Small Embryonic Like Stem Cells
• Adult Stem Cells (ASCs)
• Induced Pluripotent Stem Cells (iPSCs)

Therapy Types Covered:

• Allogenic
• Autologous

Technologies Covered:

• Expansion and Sub-Culture
• Cell Production
• Cryopreservation
• Cell Acquisition

Applications Covered:

• Drug Discovery and Development
• Regenerative Medicine

End Users Covered:

• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• Hospitals & Cell Banks

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances